In the FLOW trial, which enrolled 3533 patients, treatment with Semaglutide (Table 2), a 24% reduction was observed in the urine albumin-to-creatinine ratio, alongside a decreased incidence of acute kidney injury, attenuation of CKD progression and a lower risk of progression to kidney transplantation
(Its notable that, in general, inflammation is more likely to fall during GLP-1 treatment.) But to be safe, its worth watching your white blood cells
Patient demographics such as age and gender, along with dosage, treatment duration, presenting symptoms, imaging results, causality assessment (using Naranjo scale) ( 2.2 Phamacovigilance analysis This retrospective pharmacovigilance analysis is based on real-world data sourced from individual case safety reports (ICSRs) submitted to the FAERS
Treatments are available at both Ankeny and West Des Moines locations
Accumulated clinical evidence suggests that GLP-1RAs not only show no increase in pancreatic cancer risk among diabetic patients but potentially confer a protective effect [26]
